Recon: Pfizer raises profit forecast on cancer, heart drug sales amid declining COVID revenue; Sanofi sues Sarepta over gene therapy patents
Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.In Focus: US
- Patients push back against Novo Nordisk move to scrap an insulin product (Reuters)
- Ozempic linked to less tobacco-related healthcare use in study (Reuters)
- Pfizer lifts profit forecast on strong sales of cancer, heart drugs (Reuters)
- Sanofi sues Sarepta over US patents for gene therapy treatments (Reuters)
- Novo's older obesity drug shows biological effect on Alzheimer's patients in small trial (Reuters)
- BioNTech's cancer drug meets primary endpoint in Phase 2 trial (Reuters)
- Grifols takes $494 mln writedown on Chinese investment (Reuters)
- Concern over Merck's Gardasil sales in China sink shares (Reuters)
- Italy's Recordati hikes 2024 guidance after core profit rises 11.5% (Reuters)
- Granules India's Q1 profit nearly triples on strong demand (Reuters)
- How artificial intelligence can bolster Europe’s competitive edge in biopharma (STAT)
- Incyte touts 2 trial wins for PD-1 drug Zynyz, eyes comeback in anal cancer (Fierce)
- EU To Launch New Platform For Tackling Shortages Of ‘Critical’ Medicines In Health Crises (Pink Sheet)
- EU Pilot On Raw Data Analysis Shows Benefits For Streamlining Medicines Evaluation (Pink Sheet)
- Imunon shares up over 150% as ovarian cancer treatment extends survival in Phase 2 (Endpoints)
- Celldex says antibody drug improves irritable skin condition in Phase 2 test (Endpoints)
- Startup aims to tackle ‘undruggable’ neuro targets with tech from Kevan Shokat's UCSF lab (Endpoints)
- Keytruda tops $7B quarterly sales for the first time (Endpoints)
- Italy's Amplifon posts flat Q2 net profit on weak Europe demand (Reuters)
- Dialysis firm FMC cuts outlook for US treatment volumes, shares fall (Reuters)
- FDA officials outline benefits of AI lifecycle management (MedtechDive)
- Hologic quarterly profit rises on strong demand for its women's health products (Reuters)
- The Case For Quality: The Value Of The Voluntary Improvement Program (MedtechInsight)
- Verily to relocate its HQ from San Francisco to Dallas (Fierce)
- Patient shares a day in the life with diabetes at FDA’s first Home Health Hub meeting (MedtechDive)
- How Orange Book Antitrust Scrutiny Is Intensifying (Law360)
A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.
